Suicide risk in hepatitis C and during interferon-alpha therapy: A review and clinical update

Journal of Viral Hepatitis

Volumn 18, Issue 3, 2011, Pages 153-160

  Sockalingam, S ^a,b,c   Links, P S ^c,d   Abbey, S E ^a,b,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b Medical Psychiatry Program   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Department of Suicide Studies ^*  (Canada)

Author keywords

depression; hepatitis C; interferon alpha; suicide

Indexed keywords

ALPHA INTERFERON; CITALOPRAM; PAROXETINE; PEGINTERFERON ALPHA; RIBAVIRIN; TRYPTOPHAN;

DEPRESSION; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MELANOMA; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SUICIDAL IDEATION; SUICIDE ATTEMPT; SUPPLEMENTATION;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; RIBAVIRIN; RISK FACTORS; SUICIDE;

EID: 79951482583     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01393.x     Document Type: Review

References (63)

1. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341-344.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562. (Pubitemid 29384163)
3. Dieperink E, Willenbring ML, Ho SB,. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867-876. (Pubitemid 30412335)
4. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M,. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237-241. (Pubitemid 35351283)
5. Horikawa N, Yamazaki T, Izumi N, Uchihara M,. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003; 25: 34-38. (Pubitemid 36173783)
6. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P,. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007; 103: 83-90. (Pubitemid 47445756)
7. Ademmer K, Beutel M, Bretzel R, Clemens J, Reimer C,. Suicidal ideation with IFN-α and ribavirin in a patient with hepatitis C. Psychosomatics 2001; 42 (4): 365-367. (Pubitemid 32692115)
8. Sockalingam S, Balderson K,. Major depressive episode with psychotic features induced pegylated interferon-alpha-2b and ribavirin treatment. Int Clin Psychopharmacol 2005; 20: 289-290. (Pubitemid 41192150)
9. El-Sarag HB, Kunik M, Richardson P, Rabaneck L,. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476-482. (Pubitemid 34827192)
10. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007; 21 (Suppl. C): 25C-34C. (Pubitemid 47177083)
11. Strader DB, Wright T, Thomas DL, Seeff LB,. Diagnosis, management and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
12. Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbdities. Dig Dis Sci 2007; 52: 3251-3258. (Pubitemid 47512531)
13. Rowan PJ, Dunn NJ, El-Serag HB, Kunik ME,. Views of hepatitis C virus patients delayed from treatment for psychiatric reasons. J Viral Hepat 2007; 14 (12): 883-889. (Pubitemid 350211411)
14. Kristiansen MG, Lochen ML, Gutteberg TJ, Mortensen L, Eriksen BO, Florholmen J,. Total and cause-specific mortality rates in a prospective study of community-acquired hepatitis C virus infection in northern Norway. J Viral Hepat 2010; doi:.
15. Grassi L, Mondardini D, Pavanati M, Sighinolfi L, Serra A, Ghinelli F,. Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. J Affect Disord 2001; 64: 195-202. (Pubitemid 32324212)
16. Copeland L, Budd J, Robertson JR, Elton RA,. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch Intern Med 2004; 164 (11): 1214-1220. (Pubitemid 39030358)
17. Roy E, Haley N, Leclerc P, Sochanski B, Boudreau JF, Bovin JF,. Mortality in a cohort of street youth in Montreal. JAMA 2004; 292: 569-574. (Pubitemid 39014408)
18. Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus seropositive blood donors. Am J Epidemiol 2008; 167 (6): 743-750. (Pubitemid 351430942)
19. Lee DH, Jamal H, Regenstein FG, Perrilo RP,. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997; 42: 186-191. (Pubitemid 27059942)
20. Nguyen HA, Miller AI, Dieperink E, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002; 97 (7): 1813-1820. (Pubitemid 34761412)
21. Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ,. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001; 42: 411-415. (Pubitemid 33032113)
22. Raja M, Azzoni A, Pucci D,. Characteristics of HCV positive patients in an Italian urban psychiatric unit. Clin Pract Epidemiol Ment Health 2006; 2: 26.
23. Fattovich G, Giustina G, Favarato S, Ruol A,. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47.
24. Yu ML, Dai CY, Lee LP, et al. Outcome of chronic hepatitis C patient who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. Antivir Ther 2006; 11 (8): 1015-1019.
25. Evon DM, Ramcharren D, Belle SH, Terrault NA, Fontana RJ, Fried MW,. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol 2009; 104 (12): 2949-2958.
26. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willnebring ML,. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004; 26: 237-240. (Pubitemid 38581929)
27. Rifflet H, Vuillemin E, Oberti F, et al. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy iwth interferon alpha. Gastroenterol Clin Biol 1998; 22 (3): 353-357. (Pubitemid 28182847)
28. Cheng YC, Chen CC, Ho AS, Chiu NY,. Prolonged psychosis associated with interferon therapy in a patient with hepatitis C: case study and literature review. Psychosomatics 2009; 50 (5): 538-542.
29. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010; 15 (4): 393-403.
30. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22 (1): 86-90. (Pubitemid 34101297)
31. Wichers MC, Kenis G, Koek GH, Robaeys G, Nicholson N, Maes M,. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not cortisol. J Psychosom Res 2007; 62: 207-214. (Pubitemid 46161588)
32. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M,. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538-544. (Pubitemid 40897037)
33. Zignego AL, Cozzi A, Carpenedo R, et al. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. Dig Liver Dis 2007; 39 (Suppl. 1): S107-S111. (Pubitemid 47528200)
34. McCloskey MS, Ben-Zeev D, Lee R, Berman ME, Coccaro EF,. Acute tryptophan depletion and self-injurious behavior in aggressive patients and health volunteers. Psychopharmacology (Berl) 2009; 203 (1): 53-61.
35. Booij L, Swenne CA, Brosschot JF, Haffmans PM, Thayer JF, Van der Does AJ,. Tryptophan depletion affects heart rate variability and impulsivity in remitted depressed patients with a history of suicidal ideation. Biol Psychiatry 2006; 60 (5): 507-514. (Pubitemid 44292162)
36. Schaefer M, Winterer J, Sarkar R, et al. Three cases of successful tryptophan add-on or monotherapy of hepatitis C and IFN alpha-associated mood disorders. Psychosomatics 2008; 49 (5): 442-446.
37. Nordstrom P, Samuelsson M, Asberg M, et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat Behav 1994; 24 (1): 1-9. (Pubitemid 24116677)
38. Samuelsson M, Jokinen J, Nordstrom AL, Nordstrom P,. CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters. Acta Psychiatr Scand 2006; 113 (1): 44-47. (Pubitemid 43339088)
39. Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ,. Aggressivity, suicide attempts and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry 2001; 50: 783-791. (Pubitemid 33086766)
40. Raison CL, Borisov AS, Majer M, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 2009; 65 (4): 296-303.
41. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-389. (Pubitemid 36877077)
42. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG,. Risk of depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009; 65 (4): 344-348.
43. Pierucci-Lagha A, Covault J, Bonkovsky HL, et al. A functional serotonin transporter polymorphism and depressive effect associated with interferon-alpha treatment. Psychosomatics 2010; 51: 137-148.
44. Risch N, Herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression. JAMA 2009; 301 (23): 2462-2471.
45. Lindqvist D, Janelidze S, Hagell P, et al. Interleukin-6 is elevated in cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009; 66 (3): 287-292.
46. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105 (1): 45-55. (Pubitemid 34015882)
47. Wichers KC, Koek GH, Robaeys G, Praamstra AJ, Maes M,. Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med 2005; 35: 433-441. (Pubitemid 40372481)
48. Dieperink E, Ho SB, Thuras O, Willenbring ML,. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104-112. (Pubitemid 36241123)
49. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H,. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54: 565-572.
50. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41-48.
51. Kraus MR, Schafer A, Al-Taie O, Scheurlen M,. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005; 12: 96-100. (Pubitemid 40188781)
52. Raison CL, Woolwine BJ, Demetrashvili M, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163-1174. (Pubitemid 46650303)
53. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-966. (Pubitemid 32240314)
54. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793-798. (Pubitemid 40693194)
55. Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomized, double-blind, placebo-controlled study. Gut 2008; 57 (4): 531-536. (Pubitemid 351442539)
56. Fontana RJ, Kronfol Z, Lindsay KL, et al. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol 2008; 103 (11): 2766-2775.
57. Kalyoncu OA, Tan D, Mirsal H, Pektas O, Beyazyurek M,. Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser. J Psychopharmacol 2005; 19: 102-105.
58. Nickel T, Sonntag A, Backmund M, Pollmacher T,. Depression during therapy with interferon alpha - how long should antidepressant treatment last? Pharmacopsychiatry 2005; 38 (2): 102-104. (Pubitemid 40388793)
59. Miyaoka H, Otsubo T, Kamijima K, Ishii M, ONuki M, Mitamura K,. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156: 1120. (Pubitemid 29302822)
60. Castera L, Ziganta F, Bastie A, Buffer C, Dhumeaux D, Hardy P,. Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology 2002; 35: 978-979. (Pubitemid 34258398)
61. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric groups. Hepatology 2003; 37: 443-451. (Pubitemid 36152544)
62. Beratis S, Katrivanou A, Georgiou S, et al. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. J Psychosom Res 2005; 58 (1): 15-18. (Pubitemid 40354337)
63. Quarantini LC, Bressan RA, Galvao A, Batista-Neves S, Parana R, Miranda-Scippa A,. Incidence of psychiatric side effects during pegylated interferon-alpha retreatment in nonresponder hepatitis C virus-infected patients. Liver Int 2007; 27 (8): 1098-1102. (Pubitemid 47399444)